Skye Bioscience announced that the Company has received approval to list its common stock on the Nasdaq Global Market stock exchange. The Company’s common stock is expected to commence trading on Nasdaq at the market open on Thursday, April 11th, 2024, under the ticker symbol “SKYE“. The Company’s common stock will no longer trade on the over-the-counter securities market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience Strengthens Nasdaq Compliance with Pro Forma Balance Sheet
- Skye Bioscience price target raised to $20 from $12 at Piper Sandler
- Skye Bioscience Announces Board Expansion and Leadership Changes
- Skye Bioscience appoints Jenkins to board of directors
- Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
